First-line tislelizumab, pegaspargase, and gemcitabine with consolidative radiotherapy for early-stage extranodal NK/T-cell lymphoma: a single-arm, phase II trial
First-line tislelizumab, pegaspargase, and gemcitabine with consolidative radiotherapy for early-stage extranodal NK/T-cell lymphoma: a single-arm, phase II trial. // Clinical Lymphoma, Myeloma & Leukemia. – URL: https://www.sciencedirect.com/science/article/pii/S2152265026040346?dgcid=rss_sd_all
First-line tislelizumab, pegaspargase, and gemcitabine with consolidative radiotherapy for early-stage extranodal NK/T-cell lymphoma: a single-arm, phase II trial. Clinical Lymphoma, Myeloma & Leukemia. https://www.sciencedirect.com/science/article/pii/S2152265026040346?dgcid=rss_sd_all
“First-line tislelizumab, pegaspargase, and gemcitabine with consolidative radiotherapy for early-stage extranodal NK/T-cell lymphoma: a single-arm, phase II trial.” Clinical Lymphoma, Myeloma & Leukemia.
@article{article41109,
title = {First-line tislelizumab, pegaspargase, and gemcitabine with consolidative radiotherapy for early-stage extranodal NK/T-cell lymphoma: a single-arm, phase II trial},
journal = {Clinical Lymphoma, Myeloma \& Leukemia},
url = {https://www.sciencedirect.com/science/article/pii/S2152265026040346?dgcid=rss_sd_all}
}